Using directed molecular evolution coupled with high throughput genetic selections and screening strategies his group has successfully engineered several therapeutic enzymes technologies that are currently in clinical trials including an engineered human Arginase for cancer therapy and for treatment of hyperargininemia. Everett is also scientific cofounder of two biopharmaceutical startup companies (Aeglea Biotherapeutics and Kyn Therapeutics) where he serves as consultant in the clinical development of therapeutic enzyme technologies.